---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296538423.md"
description: "During Thursday's after-market session, several healthcare stocks saw significant movement. Gainers included Werewolf Therapeutics (HOWL), which surged 77.1% to $0.76, and Profusa (PFSA), up 14.39%. Other gainers were CytoSorbents, Tenon Medical, Revelation Biosciences, and USBC. Conversely, losers included ZeroStack (ZSTK), down 12.6%, EXoZymes, Aveanna Healthcare Holdings, Addex Therapeutics, rYojbaba, and Modular Medical."
datetime: "2026-08-20T21:06:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296538423.md)
  - [en](https://longbridge.com/en/news/296538423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296538423.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Werewolf Therapeutics** (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday's after-market session. The company's market cap stands at $19.8 million.
-   **Profusa** (NASDAQ:PFSA) stock rose 14.39% to $8.66. The market value of their outstanding shares is at $7.1 million. The company's, Q2 earnings came out today.
-   **CytoSorbents** (NASDAQ:CTSO) shares moved upwards by 9.22% to $0.34. The market value of their outstanding shares is at $22.3 million.
-   **Tenon Medical** (NASDAQ:TNON) stock moved upwards by 7.14% to $7.58. The company's market cap stands at $7.6 million.
-   **Revelation Biosciences** (NASDAQ:REVB) shares increased by 5.6% to $1.13. The company's market cap stands at $4.4 million.
-   **USBC** (AMEX:USBC) shares increased by 5.1% to $0.44. The company's market cap stands at $156.4 million.

### Losers

-   **ZeroStack** (NASDAQ:ZSTK) shares declined by 12.6% to $5.15 during Thursday's after-market session. The company's market cap stands at $11.9 million.
-   **EXoZymes** (NASDAQ:EXOZ) stock fell 9.42% to $6.45. The company's market cap stands at $59.4 million. As per the press release, Q2 earnings came out 4 days ago.
-   **Aveanna Healthcare Hldgs** (NASDAQ:AVAH) stock declined by 9.41% to $11.75. The company's market cap stands at $2.8 billion.
-   **Addex Therapeutics** (NASDAQ:ADXN) shares declined by 7.66% to $4.22.
-   **rYojbaba** (NASDAQ:RYOJ) shares declined by 6.76% to $4.39. The market value of their outstanding shares is at $51.9 million.
-   **Modular Medical** (NASDAQ:MODD) stock fell 5.25% to $3.25. The company's market cap stands at $17.9 million. The company's, Q1 earnings came out 4 days ago. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md)
- [RYOJ.US](https://longbridge.com/en/quote/RYOJ.US.md)
- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)
- [USBC.US](https://longbridge.com/en/quote/USBC.US.md)
- [ADXN.US](https://longbridge.com/en/quote/ADXN.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)
- [TNON.US](https://longbridge.com/en/quote/TNON.US.md)
- [AVAH.US](https://longbridge.com/en/quote/AVAH.US.md)
- [REVB.US](https://longbridge.com/en/quote/REVB.US.md)
- [MODD.US](https://longbridge.com/en/quote/MODD.US.md)
- [ZSTK.US](https://longbridge.com/en/quote/ZSTK.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)
- [TNONW.US](https://longbridge.com/en/quote/TNONW.US.md)
- [REVBW.US](https://longbridge.com/en/quote/REVBW.US.md)

## Related News & Research

- [One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story](https://longbridge.com/en/news/296626964.md)
- [Werewolf Therapeutics announces USD 150 million oversubscribed private placement of shares, pre-funded warrants](https://longbridge.com/en/news/296615370.md)
- [CytoSorbents releases investor presentation on blood purification devices for ICU, cardiac surgery use](https://longbridge.com/en/news/296280537.md)
- [Revelation Biosciences names Avance Clinical as CRO for Phase 2/3 Gemini AKI trial](https://longbridge.com/en/news/296359881.md)
- [EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization](https://longbridge.com/en/news/296532185.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**